The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease

Autor: Hadassa M. Jochemsen, Mirjam I. Geerlings, Wiesje M. van der Flier, Philip Scheltens, Majon Muller, Emma L. Ashby, Ruth E. Jones, Patrick G. Kehoe, Charlotte E. Teunissen
Přispěvatelé: Neurology, Clinical chemistry, Internal medicine, NCA - neurodegeneration
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Zdroj: Alzheimer's Research and Therapy, 6(3)
Alzheimer's Research & Therapy, 6(3):27. BioMed Central
Alzheimer's Research & Therapy
Jochemsen, H M, Teunissen, C E, Ashby, E L, van der Flier, W M, Jones, R E, Geerlings, M I, Scheltens, P, Kehoe, P G & Muller, M 2014, ' The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease ', Alzheimer's Research & Therapy, vol. 6, no. 3, 27, pp. 27 . https://doi.org/10.1186/alzrt257
ISSN: 1758-9193
DOI: 10.1186/alzrt257
Popis: Introduction Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer’s disease (AD) as ACE functions to degrade amyloid-β (Aβ). Therefore, we investigated whether ACE protein and activity levels in cerebrospinal fluid (CSF) and serum were associated with CSF Aβ, total tau (tau) and tau phosphorylated at threonine 181 (ptau). Methods We included 118 subjects from our memory clinic-based Amsterdam Dementia Cohort (mean age 66 ± 8 years) with subjective memory complaints (n = 40) or AD (n = 78), who did not use antihypertensive drugs. We measured ACE protein levels (ng/ml) and activity (RFU) in CSF and serum, and amyloid β1–42, tau and ptau (pg/ml) in CSF. Results Cross-sectional regression analyses showed that ACE protein level and activity in CSF and serum were lower in patients with AD compared to controls. Lower CSF ACE protein level, and to a lesser extent serum ACE protein level and CSF ACE activity, were associated with lower CSF Aβ, indicating more brain Aβ pathology; adjusted regression coefficients (B) (95% CI) per SD increase were 0.09 (0.04; 0.15), 0.06 (0.00; 0.12) and 0.05 (0.00; 0.11), respectively. Further, lower CSF ACE protein level was associated with lower CSF tau and ptau levels; adjusted B’s (95% CI) per SD increase were 0.15 (0.06; 0.25) and 0.17 (0.10; 0.25), respectively. Conclusions These results strengthen the hypothesis that ACE degrades Aβ. This could suggest that lowering ACE levels by for example ACE-inhibitors might have adverse consequences for patients with, or at risk for AD.
Databáze: OpenAIRE
Externí odkaz: